Aclaris Therapeutics, Inc.·4

Mar 4, 6:09 PM ET

Shanler Stuart 4

4 · Aclaris Therapeutics, Inc. · Filed Mar 4, 2019

Insider Transaction Report

Form 4
Period: 2019-03-01
Shanler Stuart
Chief Scientific Officer
Transactions
  • Award

    Restricted stock units

    2019-03-01+82,20082,200 total
    Common Stock (82,200 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
  • [F2]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION